Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Return on Sales (2022 - 2025)

Stoke Therapeutics has reported Return on Sales over the past 4 years, most recently at 41.24% for Q4 2025.

  • Quarterly results put Return on Sales at 41.24% for Q4 2025, down 4077.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (up 240.0% YoY), and the annual figure for FY2025 was 0.04%, up 239.0%.
  • Return on Sales for Q4 2025 was 41.24% at Stoke Therapeutics, down from 3.61% in the prior quarter.
  • Over the last five years, Return on Sales for STOK hit a ceiling of 0.71% in Q1 2025 and a floor of 41.24% in Q4 2025.
  • Median Return on Sales over the past 4 years was 6.84% (2023), compared with a mean of 8.12%.
  • Biggest five-year swings in Return on Sales: soared 916bps in 2024 and later plummeted -4077bps in 2025.
  • Stoke Therapeutics' Return on Sales stood at 7.86% in 2022, then decreased by -23bps to 9.64% in 2023, then skyrocketed by 95bps to 0.47% in 2024, then plummeted by -8631bps to 41.24% in 2025.
  • The last three reported values for Return on Sales were 41.24% (Q4 2025), 3.61% (Q3 2025), and 1.7% (Q2 2025) per Business Quant data.